Chemoembolization in Conjunction with Bevacizumab: Preliminary Results
Journal of Vascular and Interventional Radiology, ISSN: 1051-0443, Vol: 29, Issue: 9, Page: 1236-1239
2018
- 5Citations
- 17Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations5
- Citation Indexes5
- CrossRef1
- Captures17
- Readers17
- 17
Article Description
Transarterial chemoembolization is an effective, minimally invasive therapy that is widely used for treatment of unresectable colorectal cancer liver metastases (CRC-LM). However, chemoembolization induces a hypoxic microenvironment, which increases neoangiogenesis and may promote early progression. For this reason, transarterial chemoembolization efficacy may be improved by combining it with an angiogenesis inhibitor, such as bevacizumab. This report shows that transarterial chemoembolization with irinotecan-loaded polyethylene glycol embolics and bevacizumab therapy was effective and well tolerated by 6 patients with CRC-LM, resulting in a disease control rate of 83% and an overall improvement in quality of life.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S1051044318311254; http://dx.doi.org/10.1016/j.jvir.2018.04.022; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85051929426&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/30146190; https://linkinghub.elsevier.com/retrieve/pii/S1051044318311254; https://dx.doi.org/10.1016/j.jvir.2018.04.022
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know